According to the statistics from Zhi Medicine Bureau, in July 2024, there were a total of24 institutionsInvolved new drug R&D companies have completed a new round of financing, with a disclosed total amount of approximatelyRMB 4.083 billion。
Financing Overview
In July's financing events, early-stage projects remained the darlings of the capital market, with 15 disclosed financing activities. There were 2 financing cases at the B-round stage, 1 at the C-round, in addition to 3 strategic financings, and another 3 undisclosed events.In terms of disclosed amounts,There were a total of 12 financing events reaching the billion-yuan level., the market gradually became active. Riding the wave of nucleic acid drugs,AusperBioFollowing the completion of a 100 million RMB Pre-A+ round in November last year, AusperBio has secured an additional 37 million RMB in Series A funding in less than a year. Currently, the three major pipelines laid out by AusperBio—its small nucleic acid drug platform for hepatitis B cure, its therapeutic vaccine platform for hepatitis B treatment, and its collaboratively developed intranasal antibody platform—have all entered the clinical application stage.Another small nucleic acid drug research and development companyASOcura, which also completed nearly 100 million yuan in Series A financing, with state-owned capital participation.Rona TherapeuticsFocuses on the research, development, and production of nucleic acid drugs, primarily targeting disease areas such as metabolism, central nervous system, ophthalmology, and oncology, and has secured a $35 million Series A+ round of financing participated by Eli Lilly.AI Platform for Developing Small Molecule Drugs Targeting RNAReviR TherapeuticsSimilarly, it secured $30 million in Series A financing. Seeking dollar funds has also become another popular way for pharmaceutical companies to gain financial support.CGT (Cell and Gene Therapy) Track Remains Hot. Spin-off from Lu ye Pharma, SubsidiaryLu ye Pharma (Shenzhen) Co., Ltd.Received a strategic investment of up to 1.6 billion yuan from Shenzhen Green Leaf Private Equity Investment Fund, becoming the largest financing in Shenzhen this year and the highest disclosed financing amount in China's biopharmaceutical field this month.Zhiyuan MedicalFocused on Developing Allogeneic Fibroblast Therapy, Providing Novel Cellular Solutions for Patients with Degenerative Disc Disease, Completing Angel Round Financing Worth Tens of Millions of Yuan.AnotherUniXelI BIOTECHNOLOGYCompleted over 100 million yuan in Series A financing, with Pudong Venture Capital as the investor. The company focuses on developing a new generationCell Therapy Drugs Based on Human Pluripotent Stem Cell Technology, utilizing a technology platform for the preparation, culture, differentiation, and gene editing of human pluripotent stem cells, is committed to the research and development of technology and products in the field of stem cell therapy.。Moreover, the ADC drug development and CDMO fields remain hotbeds of investment.Wuxi Zhikang Hongyi Biotechnology Co., Ltd. and Dassault PharmaAlso a developer of Antibody-Drug Conjugates (ADC), Wuxi Zhikang Hongyi Biotechnology Co., Ltd. has attracted attention from Xichuang Investment, Binhu Industrial Group, and WuXi Biologics, securing hundreds of millions in funding.CDMO EnterpriseShanghai Lingkang Era Biotechnology Co., Ltd.Relying on its dual-core platforms of mammalian cell and microbial platforms, it provides one-stop services for the entire process of drug development from research to commercial production. This month, it completed a 190 million yuan B-round financing.From the perspective of financing geographical distribution,Yangtze River Delta and Pearl River Delta regions, further solidifying its leading position in biopharmaceutical industry investments. In this round of financing activities, 12 companies in one location and 8 companies in another successfully secured funding. Additionally, companies in Shandong, Hubei, Beijing, and Chongqing have also announced successful financing. The investment enthusiasm in the biopharmaceutical industry is spreading to a wider geographic area.R&D financing events this month involved nucleic acid drugs, cell and gene therapy drugs, large molecule drugs, peptide drugs, live bacterial drugs, synthetic biology, and more.The disclosed financing events cover multiple therapeutic areas, including cancer treatment, neurological diseases, rare diseases, metabolic diseases, autoimmune diseases, and anti-aging.The following is a summary of financing events:
Details of Financing Events Exceeding 100 Million Yuan
Amount: Billion-level RMBYaoSu Technology Announces Completion of Angel+ Round Financing Worth Hundreds of Millions of RMB, Led by TriApex Group, with Follow-up Investments from Zhengxuan Investment and Tiantu Investment; Existing Shareholders Legend Capital and Yae Capital Continue to Increase Their Investments.YaoSu Technology, founded in Boston, USA, at the end of 2021, is a biotech startup company that integrates organoid-on-a-chip, high-content three-dimensional (3D) cell imaging, computer vision (CV), and artificial intelligence (AI) technologies to apply to drug discovery as the "3D-Wet-AI" platform. By generating large-scale 3D cellular images on organ chips and constructing complex networks of interactions between gene clusters and compound structures, it provides more accurate disease and drug efficacy evaluation models. Combined with AI technology, it rapidly screens out the most promising drug candidates with the highest development value.Amount: Billion-level RMBAusperBio Announces Completion of $37 Million Series A Financing. This round of financing was led by InnoPinnacle Fund, with participation from Vivo Capital, H&Q China, Qiming Venture Partners, and Yuan Bio Capital.AusperBio is a research and development company focused on small nucleic acid drugs for hepatitis B. It is committed to developing innovative drugs and vaccines for the treatment and prevention of chronic hepatitis B and other major infectious diseases. Currently, AusperBio’s three major innovative pipelines—small nucleic acid drug platform for HBV cure, therapeutic vaccine platform for HBV treatment, and the intranasal antibody platform developed in collaboration—have all entered the clinical application stage.Amount: 30 million US dollarsReviR Therapeutics Completes $30 Million Series A Financing Round, Led by Lapam Investment, with Continuous Investment from Existing Shareholders CDH Investments, FiveSource Capital, and Yabai Capital, and Participation from XtalPi and CMT Research Foundation.ReviR Therapeutics is a developer of small molecule drugs targeting RNA, driven by artificial intelligence algorithms and gene technology to innovate drug discovery. Focused on RNA spatial structure computation, it has built the voyageRTM AI platform to develop small molecule drugs targeting RNA, addressing long-standing unmet clinical needs such as cancer and rare diseases.Amount: Over 20 million US dollarsZean BioPharmaceutical Company Announces Completion of Series A Financing, Raising Over 20 Million USD. This Round of Financing Was Led by Lapam Investment, with Participation from Hillhouse Ventures, and Additional Investments from Existing Shareholders such as Qiming Venture Partners, K2VC, and Shunwei Capital.LTZ is committed to developing novel immunotherapies based on the "Myeloid Engager Platform" technology to better address unmet clinical needs in areas such as cancer and autoimmune diseases.Amount: 35 million US dollarsRona Therapeutics Completes $35 Million Series A+ Financing. This round of financing was led by LongRiver Jiangyuan Investment, with participating investors including Zhaode Investment, Boyuan Capital, Zhongqi Capital, and Lilly Asia Ventures, among others.Rona TherapeuticsIt is a nucleic acid drug developer, focusing on the research, development, and production of nucleic acid drugs, primarily targeting disease areas such as metabolism, central nervous system, ophthalmology, and oncology.Amount: Hundreds of millions of yuanThis round of financing was led by Xichuang Investment and Binhu Industrial Group, with existing shareholders such as Wuxi Biologics continuing to increase their investment.Wuxi Zhikang Hongyi Biotechnology Co., Ltd. is currently actively advancing the clinical development of multiple drugs in the fields of oncology and nephrology. Among them, the core oncology product—BC3195, a globally exclusive ADC drug targeting CDH3—is conducting dose-expansion research across multiple cohorts in Phase Ib clinical trials simultaneously in China and the United States. The core nephrology product—SC0062, a potentially best-in-class highly selective ETA small molecule antagonist—is nearing completion of the Phase II 2-SUCCEED study, with efforts to initiate Phase III clinical trials within the year.Shanghai Lingkang Era Biotechnology Co., Ltd.Shanghai Lingkang Era Biotechnology Co., Ltd. Secures 190 Million Yuan in Series B Financing, Led by Zhongshan Venture Capital with Follow-on Investment from Cuiheng Venture Capital; Xibay Capital and Others Also Participated in This Round.Shanghai Lingkang Era Biotechnology Co., Ltd. is a biologics CDMO service provider. Relying on its robust dual-core platforms — mammalian cell platform and microbial platform, it offers comprehensive CDMO services ranging from druggability assessment, preparation of high-quality pharmacology and toxicology study samples, to process development, clinical submission support services, as well as clinical sample production and commercial manufacturing.Shanghai Luqi Biomedical Technology Co., Ltd. announced the successful completion of a nearly 200 million RMB B2 round of financing. This round was led by Qiming Venture Partners, with participation from Huangpu Biomedical Industry Fund and Jiuyu Investment. Existing shareholder Shengdi Investment continued to increase its investment.Lokqi Bio is committed to the research and development of innovative nanobody drugs. The inhalable nanobody asthma treatment drug LQ036 has completed Phase I clinical trials in China and Australia, and Phase II clinical trials in China are currently underway. The LQ043H project has completed Phase Ia clinical trials in China, and the Phase Ib/II clinical trials will be accelerated based on the funding from this round of financing.Amount: Hundreds of millions of yuanThis round of financing was led by Shanghai BioPharmaceutical Fund, with follow-up investments from Shanghai Science and Technology Innovation Group, Baoshan State Investment Group, and existing shareholder Center Laboratories Limited.Baoji Pharmaceutical is a biopharmaceutical R&D and production enterprise, operating as a Sino-foreign joint venture that integrates drug research and development with production. The company specializes in the scalable production of recombinant protein drugs and recombinant antibody drugs, focusing on providing solutions for clinical needs.Round: Strategic InvestmentAmount: Hundreds of millions of yuanShenzhen Lu ye Pharma Obtains Strategic Investment of Up to 1.6 Billion RMB from Shenzhen Green Leaf Private Equity Investment Fund.Shenzhen Lu ye Pharma is an innovative drug research and development producer, focusing on the R&D, production, and sales of innovative drugs. The company has reached an internationally advanced level in advanced drug delivery technology fields such as microspheres, liposomes, and transdermal drug delivery. It has achieved multiple accomplishments in new molecular entities and bio-antibodies and is also making arrangements and developments in cell therapy and gene therapy.Round: Strategic InvestmentKangfude Pharmaceutical Receives 120 Million Yuan Investment from Disono Pharmaceutical for the Construction of a Full Peptide Industry Chain at Its Subsidiary, Chongqing Xingtaihao Pharmaceutical Co., Ltd., Supporting Chongqing International Bio City in Competing in the New Peptide Drug Sector and Fostering New Productive Forces in Biomedicine.Chongqing Kangfude is a research and production enterprise of anti-tumor active pharmaceutical ingredients (APIs), mainly producing taxane-based and other highly active, highly toxic anti-tumor APIs. Its representative products include paclitaxel, docetaxel, cabazitaxel, eribulin, etc.Yanshan Technology announced that its wholly-owned subsidiary, Zhuhai Hengqin Yanhe Health Technology Co., Ltd., plans to invest 100 million yuan in Zhejiang Pukang Biotechnology Co., Ltd. After the completion of the investment, it will hold 4.7619% of its equity.Zhejiang Pukang Biotechnology Co., Ltd. is a human vaccine research and development company specializing in live attenuated hepatitis A vaccines, with its main product being the freeze-dried live attenuated hepatitis A vaccine.—The End—
Recommended Reading
